Fri. 22 Mar 2024, 4:22pm ET
Benzinga
Earnings, News
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate of $(13.77) by 39.51 percent. This is a 84.31 percent increase over losses of $(53.10) per share from the same period last year.